Clinical Trial Update: A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1/2 clinical trial of VS-505 in patients with end-stage renal disease undergoing hemodialysis to address hyperphosphatemia, sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• VS-505

Snippet

Sponsor: KDL Inc. | Conditions: End Stage Renal Disease, Hyperphosphatemia | Phase 1, Phase 2 | Status: UNKNOWN